|
|

|
|
Post-exposure Prophylaxis
In nearly all patients, IgM and IgG antibodies can be detected at the time of presentation for medical care; the antibody titer may reach its maximum level by the first blood test. Thus, the administration of IgG concentrates is unlikely to be of benefit to the patient’s immune defence at that time and is limited to administration for up to 48 hours after the tick bite. Therefore, IgG is not available any more in European countries. Especially in children the benefit-risk ratio may be negative and therefore, TBE immunoglobulin must not be used for post-exposure prophylaxis in children and adolescents up to the age of 14 years.
» Printversion
|
|
|

|
Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
» read more
Baxter receives preparedness contract from Austrian Ministry of Health for Pandemic Influenza Vaccine
» read more
Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
» read more
|
|